Alector Inc (STU:0Z2)
€ 1.69 -0.07 (-3.98%) Market Cap: 167.26 Mil Enterprise Value: -238.19 Mil PE Ratio: 0 PB Ratio: 1.47 GF Score: 55/100

Alector Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 07:25PM GMT
Release Date Price: €14.4 (-2.70%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good afternoon, and welcome to day 3 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays, and welcome. We are pleased to welcome Alector to next up for a virtual fireside chat. Representing the company is President and COO, Shehnaaz Suliman. Shehnaaz, welcome very much.

Shehnaaz Suliman
Alector, Inc. - President , COO & Interim Chief Business Officer

Thank you, Carter. It's a pleasure to be here.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

I believe you're going to make some opening comments, and then we'll hop into Q&A.

Shehnaaz Suliman
Alector, Inc. - President , COO & Interim Chief Business Officer

Absolutely, I'll be delighted to do that. So we, at Alector, have been pioneering immuno-neurology since Arnon Rosenthal founded and CEOs started the company about 8 years ago. And what that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot